Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Categories

  • ABB
  • Alps
  • Basel
  • Bern
  • Chubb
  • Geneva
  • Glencore
  • Lausanne
  • Nestlé
  • Novartis
  • Roche
  • Switzerland
  • UBS
  • Vitol
  • Zürich
  • Zurich Insurance
Switzerland
  • Europe
    • FR
    • DE
    • IT
    • ES
    • BE
    • NL
    • LU
    • DK
    • PL
    • UK
  • Switzerland
    • Basel
    • Bern
    • Geneva
    • Lausanne
    • Zürich
  • Schweiz
  • Suisse
  • Alps
  • Business
    • ABB
    • Chubb
    • Glencore
    • Nestlé
    • Novartis
    • Roche
    • UBS
    • Vitol
    • Zurich Insurance
  • NATO
  • US
  • Africa
  • Afrique

Browsing Tag

advance

4 posts
GGeneva
NeuroCatch Inc. Announces Strategic Partnership with The Geneva Foundation to Advance Cognitive Health Research for Military Personnel
Read More

NeuroCatch Inc. Announces Strategic Partnership with The Geneva Foundation to Advance Cognitive Health Research for Military Personnel

  • 2026-05-12
Vancouver, British Columbia–(Newsfile Corp. – May 12, 2026) – NeuroCatch Inc., a leader in objective cognitive brain…
GGlencore
Falcon Copper and Glencore Sign MoU to Advance U.S. Critical Minerals Supply Chain
Read More

Falcon Copper and Glencore Sign MoU to Advance U.S. Critical Minerals Supply Chain

  • 2026-04-30
Fort Collins, Colorado–(Newsfile Corp. – April 30, 2026) – Falcon Copper Corp. (“Falcon Copper” or the “Company”)…
RRoche
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Read More

Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management

  • 2026-04-29
Company announcement – No. 11 / 2026 Zealand Pharma and Roche to advance petrelintide, an amylin analog, to…
NNovartis
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors
Read More

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

  • 2026-03-27
– Acquisition brings together Excellergy’s differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise of…
Switzerland
www.europesays.com